Outpatiented · Case Knowledge
The question gets asked constantly: is there anything new for vascular dementia? The honest answer requires separating what is being used now, what is in trials, and what sounds promising but does not yet apply. This is that breakdown.
What It Actually Is
Vascular dementia happens when the brain's blood supply is damaged, through small strokes, chronically blocked vessels, or leaky vasculature, and brain cells die from oxygen deprivation. It is not a protein accumulation disease. It is a blood flow and vascular integrity disease.
Unlike Alzheimer's, where memory loss tends to dominate early, vascular dementia more often affects processing speed, executive function, focus, and decision-making first. Progression can be stepwise rather than gradual, stable for a period, then a sudden drop following another vascular event.
A useful frame: if the brain is a city, vascular dementia is what happens when roads get shut down one by one. Some neighborhoods get cut off and stop working. Which neighborhoods, and how many, determines the clinical picture.
This distinction matters for treatment because the therapies being developed for Alzheimer's, which target amyloid plaques, do not address the vascular mechanism. A patient with pure vascular dementia and a patient with Alzheimer's are dealing with different problems at the biological level, even when the cognitive symptoms overlap.
The mechanism determines the treatment.
Alzheimer's drugs do not fix blood vessels.
What Is Currently Used
There are no FDA-approved medications specifically for vascular dementia. What is being used falls into three categories: vascular risk factor management, off-label cognitive agents, and antiplatelet therapy.
Controlling blood pressure, LDL cholesterol, blood sugar, and stopping smoking slows progression more reliably than any medication currently available for vascular dementia specifically. Every additional vascular event causes more damage. Preventing those events is the primary treatment strategy. This is not a consolation prize. It is the most effective tool in the current toolkit.
Both are approved for Alzheimer's disease. They are used off-label in vascular dementia with modest evidence for cognitive benefit. Donepezil has the most data in vascular dementia specifically. Rivastigmine is also used, particularly in mixed presentations. The effect size is generally small to moderate. They are approved for vascular dementia in several non-US jurisdictions.
Approved for moderate-to-severe Alzheimer's. Used off-label in vascular dementia. Some evidence of benefit, particularly for behavioral symptoms and activities of daily living. Effect size is modest. Combination with a cholinesterase inhibitor is sometimes used in mixed presentations.
Antiplatelet agents are used to reduce the risk of additional small strokes or thromboembolic events that would cause further vascular damage. This is secondary prevention of the underlying disease mechanism, not treatment of existing cognitive impairment. The indication and choice of agent depends on the vascular history and individual risk profile.
Cilostazol improves blood flow by inhibiting platelet aggregation and dilating blood vessels. It has been used in Japan for vascular cognitive impairment and is showing meaningful results in ongoing trials. Not yet a standard of care in the US but worth discussing with a neurologist at an academic center, particularly for patients who are not candidates for standard antiplatelet therapy.
The Anti-Amyloid Drugs
Two anti-amyloid monoclonal antibodies have received FDA approval for early Alzheimer's disease: lecanemab (Leqembi, Eisai/Biogen) and donanemab (Kisunla, Eli Lilly). These are legitimately new, and the question of whether they apply to vascular dementia comes up frequently. The distinction matters.
These drugs target amyloid plaques. They require confirmed amyloid pathology via PET imaging or CSF biomarkers to qualify. A patient with pure vascular dementia, no amyloid burden, does not have a biological target for these drugs to work on.
Lecanemab was initially administered as biweekly IV infusions for 18 months. A maintenance IV option every 4 weeks was approved in January 2025. A weekly subcutaneous self-injection option was approved in August 2025, which significantly reduces the burden of administration. Indicated for MCI or mild dementia due to Alzheimer's disease with biomarker confirmation of amyloid pathology. Patients with significant vascular contributions to cognitive impairment were not a primary study population.
Donanemab is administered as monthly IV infusions and is indicated for MCI or mild Alzheimer's dementia. The exclusion criteria are critical: patients with more than 4 cerebral microbleeds, cortical superficial siderosis, or major vascular contribution to cognitive impairment are excluded. For a patient with vascular dementia, particularly one with a history of small strokes or microhemorrhages, this exclusion almost certainly applies. The vascular history that defines the diagnosis is also the disqualifier.
Both drugs carry risk of ARIA, amyloid-related imaging abnormalities, which include microhemorrhages and brain edema. This risk is meaningful in any patient, but it is substantially elevated in patients with pre-existing vascular damage. An additional concern specific to vascular patients: administration of IV tPA for acute ischemic stroke in someone taking anti-amyloid therapy poses significant bleeding risk. For a patient whose dementia came from vascular disease, these are not theoretical concerns.
Mixed dementia, Alzheimer's pathology coexisting with vascular disease, is extremely common and often underdiagnosed. If a patient clinically diagnosed with vascular dementia has not had amyloid biomarker testing, there may be concurrent Alzheimer's pathology present. In that case, amyloid PET or CSF biomarkers could reveal candidacy for anti-amyloid therapy. This is where a second opinion at an academic center with access to these biomarkers and clinical trials is most valuable.
The exclusion criteria for donanemab describe vascular dementia.
The vascular history that defines the diagnosis is also the disqualifier.
What Is Emerging
Several research threads are directly relevant to vascular dementia. None are standard of care yet, but one is close enough to clinical relevance that it is worth discussing with a neurologist.
Semaglutide (Ozempic, Wegovy) is being actively studied for vascular and mixed dementia. A 2025 study specifically examined its ability to remodel mitochondrial dynamics relevant to vascular dementia therapy. This is mechanistically plausible given semaglutide's known cardiovascular protective effects, anti-inflammatory properties, and metabolic impact. It is already an approved drug with a known safety profile, which compresses the path from promising to available. It is not yet a standard recommendation for dementia, but neurologists at academic centers are aware of this research and it is a reasonable conversation to initiate.
Researchers at the University of Vermont found that restoring a missing phospholipid (PIP2) into the circulatory system could restore normal brain blood flow and reduce dementia symptoms in preclinical models. The Piezo1 protein, which senses blood flow in vessel walls, appears to be dysregulated in vascular dementia. Still preclinical, but the mechanism is directly relevant to the vascular pathology. This is targeting the actual blood flow problem, not downstream effects.
In 2025, UCLA researchers identified a drug currently in clinical trials for psoriasis that, when administered to mice with vascular dementia, promoted brain tissue repair and recovery of memory and gait function. The shared mechanism involves neuroinflammation, the inflammatory pathways involved in psoriasis overlap with those driving vascular brain damage. Drug repurposing from an existing approved compound typically moves faster than novel agent development.
For a patient with both vascular dementia and a history of migraines, the migraine history is clinically relevant beyond what it might appear. Migraine with aura specifically is associated with increased risk of ischemic stroke and white matter lesions, the same vascular changes that contribute to vascular dementia.
The mechanism involves cortical spreading depression, transient vascular dysregulation, and in some patients, endothelial dysfunction. This is not a coincidence to note and move on from. A neurologist evaluating vascular dementia in someone with migraine history should be integrating that history into the vascular risk picture, not treating them as unrelated conditions.
Whether or not the patient's migraines contributed to her vascular dementia cannot be determined retrospectively. What can be addressed is current migraine management and vascular risk optimization as part of the same conversation.
Questions People Actually Ask
Is there anything new for vascular dementia in 2025?
Nothing new has been FDA-approved specifically for vascular dementia. What has changed: two anti-amyloid drugs (lecanemab and donanemab) are approved for early Alzheimer's and may apply to mixed dementia presentations with confirmed amyloid pathology. Semaglutide is being actively studied for vascular dementia specifically and represents the most clinically relevant emerging option. Several preclinical findings, particularly the PIP2/Piezo1 work from the University of Vermont, are targeting the vascular mechanism directly.
For a patient asking about new options, the most productive path is a second opinion at a neurological center affiliated with a university or academic medical center. These centers have access to biomarker testing that can clarify whether mixed dementia pathology is present, and access to clinical trials that community practices do not.
Can lecanemab or donanemab be used for vascular dementia?
Not for pure vascular dementia. Both are approved for early Alzheimer's disease with confirmed amyloid pathology. Donanemab specifically excludes patients with major vascular contributions to cognitive impairment in its eligibility criteria, which describes vascular dementia almost by definition.
Where it becomes relevant: mixed dementia, meaning coexisting Alzheimer's and vascular pathology, is common. If amyloid biomarker testing (PET or CSF) confirms Alzheimer's pathology alongside the vascular disease, the picture changes. A patient clinically diagnosed with vascular dementia who has not had biomarker testing may be a candidate if amyloid is confirmed, but the vascular history still means elevated ARIA risk that needs to be weighed carefully.
What is the best referral for a second opinion on vascular dementia?
A behavioral neurologist or cognitive neurology specialist at an academic medical center, university-affiliated hospitals, major health systems with dedicated memory disorder programs, or NIA-funded Alzheimer's Disease Research Centers. These centers have access to amyloid PET imaging, CSF biomarker testing, neuropsychological testing, and clinical trial enrollment that community neurology practices typically do not.
A geriatric psychiatrist with expertise in neurocognitive disorders is also appropriate, particularly if behavioral symptoms are prominent. The goal of the second opinion is both diagnostic precision, confirming the dementia type and ruling out mixed pathology, and access to the full range of emerging options including trial enrollment.
What is the difference between vascular dementia and Alzheimer's disease?
Alzheimer's disease is caused by accumulation of amyloid plaques and tau tangles that progressively damage neurons. Memory loss typically dominates the early picture. Progression is usually gradual. The anti-amyloid drugs being discussed target this mechanism.
Vascular dementia is caused by damage to the brain's blood supply, from strokes, small vessel disease, or chronically impaired perfusion, that cuts off oxygen to brain cells. It tends to affect processing speed, executive function, and attention first. Progression can be stepwise, stable periods interrupted by sudden drops following vascular events. The treatment strategy is fundamentally different: prevent further vascular damage rather than clear protein aggregates.
Mixed dementia, both pathologies present, is extremely common, particularly in older patients, and is frequently underdiagnosed because it requires biomarker testing to identify the Alzheimer's component.
Do migraines affect vascular dementia risk?
Migraine with aura specifically is an independent vascular risk factor associated with increased risk of ischemic stroke and white matter lesions. The mechanism involves cortical spreading depression, transient vascular dysregulation, and in some patients, endothelial dysfunction, the same vascular systems implicated in vascular dementia.
For a patient with both vascular dementia and a migraine history, these are not two unrelated conditions. A neurologist managing the dementia should be integrating the migraine history into the vascular risk picture. Optimizing migraine management and controlling vascular risk factors are part of the same treatment strategy.
The MAP Tool traces your health history, symptoms, and patterns to root cause. Not a diagnosis. A thread to follow.
Start Your Map